Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma
← catalyst calendarNCT07777120 · readout in 7,893 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
300estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-20
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-24 | actual | When the study began enrolling |
| Primary completion | 2048-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2048-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Marginal Zone Lymphoma
Intervention
- Biological: lisocabtagene maraleucel
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of selected adverse events after lisocabtagene maraleucel infusion
measured Up to 15 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed